About
Research
Patient Care
Education
Community
Early Investigator Advancement Program (EIAP)
Due November 1, 2022.
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers
NOT-CA-21-028. This notice applies to due dates on or after June 5, 2021, and subsequent receipt dates through January 8, 2024.
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers
NOT-CA-23-004. First available due date: January 05, 2023. Expires July 5, 2025.
AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01 Clinical Trial Not Allowed)
RFA-DE-23-013. Applications due January 27, 2023.
Advancing Adolescent Tobacco Cessation Intervention Research (R34 Clinical Trial Optional)
RFA-CA-22-042. Applications due January 23, 2023 and October 15, 2023.
Advancing Adolescent Tobacco Cessation Intervention Research (R01 Clinical Trial Required)
RFA-CA-22-043. Applications due January 23, 2023 and October 16, 2023.
Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required)
RFA-CA-22-051. Applications due December 28, 2022.
Funding Opps
Competitive funding opportunities to support Chao Family Comprehensive Cancer Center (CFCCC) members are available through both intramural and extramural sources. CFCCC shares a monthly CFCCC Bulletin to all Members, which highlights the details of upcoming funding opportunities.
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
RFA-CA-22-052. Applications due February 17, 2023.
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)
RFA-CA-22-056. Applications due December 15, 2022 and December 15, 2023.
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)
RFA-CA-22-057. Applications due December 15, 2022 and December 15, 2023.
NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed)
PAR-21-295. Standard dates apply. Expires November 13, 2024.
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 - Independent Clinical Trial Not Allowed)
PAR-21-300. Standard dates apply. Expires September 8, 2024.
NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed)
PAR-21-301. Standard dates apply. Expires September 8, 2024.
Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)
PAR-22-239. Application Due January 6, 2023.
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
PAR-22-249. Application Due January 6, 2023.
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)
RFA-CA-22-035, RFA-CA-22-036, RFA-CA-22-037. Nomination by the Cancer Center is required. Internal applications are due by December 6, 2022. Applications of selected applicants are due to NIH by February 28, 2023.
Membership Guidelines
Chao Family Comprehensive Cancer Center (CFCCC) membership is available to faculty or researchers with PI status at UCI or a non-UCI faculty member of another institution who is not a member of another NCI-designated Cancer Center and who has a substantial collaboration with a UCI Cancer Center member(s).
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 Clinical Trial Not Allowed)
RFA-CA-23-018. Applications due January 10, 2023.
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit (U24 Clinical Trial Not Allowed)
RFA-CA-23-019. Applications due January 10, 2023.